- Home
- TSAT vs AQST Comparison
TSAT vs AQST Comparison
Compare TSAT & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TSAT | AQST |
|---|---|---|
| Founded | 1969 | 2004 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 390.1M | 504.0M |
| IPO Year | 2021 | 2007 |
Fundamental Metrics
Financial Performance| Metric | TSAT | AQST |
|---|---|---|
| Price | $42.98 | $4.12 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $37.00 | $9.00 |
| AVG Volume (30 Days) | 167.7K | ★ 1.5M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,430,000.00 |
| Revenue This Year | N/A | $10.08 |
| Revenue Next Year | N/A | $49.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.77 |
| 52 Week Low | $14.81 | $2.22 |
| 52 Week High | $44.36 | $7.55 |
Technical Indicators
Market Signals| Indicator | TSAT | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 61.74 | 50.65 |
| Support Level | $22.04 | $3.70 |
| Resistance Level | $43.82 | $4.42 |
| Average True Range (ATR) | 3.44 | 0.17 |
| MACD | 0.20 | 0.01 |
| Stochastic Oscillator | 86.50 | 63.46 |
Price Performance
Historical ComparisonAbout TSAT Telesat Corporation
Telesat Corp is a satellite operator, that provides its customers with mission-critical communications services. It operates in a single operating segment, in which it provides satellite-based services to its broadcast, enterprise, and consulting customers around the world. Geographically, it derives a majority of its revenue from Canada. It derives revenue from Broadcast, Enterprise, Consulting, and others.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.